Applied Genetic Technologies Corporation
- Jurisdiction
United States - LEI
549300I3X9WJZYN79L35 - ISIN
US03820J1007 (AGTC )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
1
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Read full profile
Fundamentals
- Net revenue
€277.21K - Gross margin
100.0% - EBIT
-€44.04M - EBIT margin
-15,888.3% - Net income
-€30.07M - Net margin
-10,846.8%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: February 14, 2022 (Q2 2022)